Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
Journal
Hepatology International
Journal Volume
4
Journal Issue
2
Pages
439-474
Date Issued
2010
Author(s)
Omata M.
Lesmana L.A.
Tateishi R.
Lin S.-M.
Yoshida H.
Kudo M.
Lee J.M.
Choi B.I.
Poon R.T.P.
Shiina S.
Jia J.-D.
Obi S.
Han K.H.
Jafri W.
Chow P.
Lim S.G.
Chawla Y.K.
Budihusodo U.
Gani R.A.
Lesmana C.R.
Putranto T.A.
Liaw Y.F.
Sarin S.K.
Abstract
Introduction: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations. Methods: The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements. Results: Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference. ? 2010 Asian Pacific Association for the Study of the Liver.
Other Subjects
aflatoxin; alpha fetoprotein; bevacizumab; capecitabine; cetuximab; cisplatin; decarboxyprothrombin; doxorubicin; epidermal growth factor receptor antibody; epirubicin; erlotinib; farnoquinone; fluorouracil; gefitinib; gemcitabine; glitazone derivative; glypican 3; hepatitis B vaccine; interferon; lamivudine; metformin; mitomycin C; mitoxantrone; oxaliplatin; placebo; sorafenib; sunitinib; thalidomide; tumor marker; unindexed drug; advanced cancer; alcohol consumption; antineoplastic activity; ascites; bleeding; bone marrow suppression; cancer screening; cardiotoxicity; chemoembolization; clinical trial; coffee; computer assisted tomography; constipation; desquamation; diagnostic test; diarrhea; dizziness; drug efficacy; drug eruption; drug safety; drug tolerability; echography; edema; evidence based medicine; family history; fatigue; geographic distribution; hand foot syndrome; hemochromatosis; hepatic encephalopathy; hepatitis B; hepatitis C; human; Human immunodeficiency virus infection; hypertension; infection; insulin resistance; liver carcinoma; liver cell carcinoma; liver cirrhosis; liver resection; liver transplantation; loading drug dose; lymphocytopenia; medical specialist; mixed infection; neutropenia; nonalcoholic fatty liver; nuclear magnetic resonance imaging; positron emission tomography; primary prevention; priority journal; radiofrequency ablation; review; secondary prevention; sensitivity and specificity; sex difference; side effect; smoking; somnolence; thrombocytopenia; thrombosis; vaccination; virus transmission
Publisher
Springer New York
Type
review